Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1993 1
2011 1
2013 2
2014 1
2015 1
2016 3
2017 3
2018 4
2019 9
2020 8
2021 11
2022 12
2023 9
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Transformer-based biomarker prediction from colorectal cancer histology: A large-scale multicentric study.
Wagner SJ, Reisenbüchler D, West NP, Niehues JM, Zhu J, Foersch S, Veldhuizen GP, Quirke P, Grabsch HI, van den Brandt PA, Hutchins GGA, Richman SD, Yuan T, Langer R, Jenniskens JCA, Offermans K, Mueller W, Gray R, Gruber SB, Greenson JK, Rennert G, Bonner JD, Schmolze D, Jonnagaddala J, Hawkins NJ, Ward RL, Morton D, Seymour M, Magill L, Nowak M, Hay J, Koelzer VH, Church DN; TransSCOT consortium; Matek C, Geppert C, Peng C, Zhi C, Ouyang X, James JA, Loughrey MB, Salto-Tellez M, Brenner H, Hoffmeister M, Truhn D, Schnabel JA, Boxberg M, Peng T, Kather JN. Wagner SJ, et al. Among authors: schmolze d. Cancer Cell. 2023 Sep 11;41(9):1650-1661.e4. doi: 10.1016/j.ccell.2023.08.002. Epub 2023 Aug 30. Cancer Cell. 2023. PMID: 37652006 Free PMC article.
A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer.
Yuan Y, Lee JS, Yost SE, Frankel PH, Ruel C, Egelston CA, Guo W, Gillece JD, Folkerts M, Reining L, Highlander SK, Robinson K, Padam S, Martinez N, Tang A, Schmolze D, Waisman J, Sedrak M, Lee PP, Mortimer J. Yuan Y, et al. Among authors: schmolze d. Oncologist. 2021 Feb;26(2):99-e217. doi: 10.1002/onco.13583. Epub 2020 Nov 24. Oncologist. 2021. PMID: 33141975 Free PMC article. Clinical Trial.
Profiling the Somatic Mutational Landscape of Breast Tumors from Hispanic/Latina Women Reveals Conserved and Unique Characteristics.
Ding YC, Song H, Adamson AW, Schmolze D, Hu D, Huntsman S, Steele L, Patrick CS, Tao S, Hernandez N, Adams CD, Fejerman L, Gardner K, Nápoles AM, Pérez-Stable EJ, Weitzel JN, Bengtsson H, Huang FW, Neuhausen SL, Ziv E. Ding YC, et al. Among authors: schmolze d. Cancer Res. 2023 Aug 1;83(15):2600-2613. doi: 10.1158/0008-5472.CAN-22-2510. Cancer Res. 2023. PMID: 37145128 Free PMC article.
Advances in microscopy techniques.
Schmolze DB, Standley C, Fogarty KE, Fischer AH. Schmolze DB, et al. Arch Pathol Lab Med. 2011 Feb;135(2):255-63. doi: 10.5858/135.2.255. Arch Pathol Lab Med. 2011. PMID: 21284447 Free article. Review.
Complete response to chemoimmunotherapy with bevacizumab in synchronous multiple primary cancers: pulmonary adenocarcinoma and sarcomatoid carcinoma.
Garcia D, Mambetsariev I, Fricke J, Schmolze D, Afkhami M, Mannan R, Kim P, Therese Dingal S, Nguyen B, Babikian R, Fong Y, Salgia R. Garcia D, et al. Among authors: schmolze d. Cold Spring Harb Mol Case Stud. 2023 May 9;9(2):a006262. doi: 10.1101/mcs.a006262. Print 2023 Apr. Cold Spring Harb Mol Case Stud. 2023. PMID: 37160318 Free PMC article.
MicroRNA Regulation of T-Cell Exhaustion in Cutaneous T Cell Lymphoma.
Han Z, Estephan RJ, Wu X, Su C, Yuan YC, Qin H, Kil SH, Morales C, Schmolze D, Sanchez JF, Tian L, Yu J, Kortylewski M, Rosen ST, Querfeld C. Han Z, et al. Among authors: schmolze d. J Invest Dermatol. 2022 Mar;142(3 Pt A):603-612.e7. doi: 10.1016/j.jid.2021.08.447. Epub 2021 Nov 11. J Invest Dermatol. 2022. PMID: 34774537 Free PMC article.
Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer.
Yuan Y, Yost SE, Cui Y, Ruel C, Murga M, Tang A, Martinez N, Schmolze D, Waisman J, Patel N, Vora L, Tumyan L, Bozoghlanian M, Stewart D, Frankel PH. Yuan Y, et al. Among authors: schmolze d. Oncologist. 2023 Jul 5;28(7):e498-e507. doi: 10.1093/oncolo/oyad026. Oncologist. 2023. PMID: 37023705 Free PMC article. Clinical Trial.
Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer.
Egelston CA, Guo W, Yost SE, Ge X, Lee JS, Frankel PH, Cui Y, Ruel C, Schmolze D, Murga M, Tang A, Martinez N, Karimi M, Somlo G, Lee PP, Waisman JR, Yuan Y. Egelston CA, et al. Among authors: schmolze d. Cancer Immunol Immunother. 2023 Sep;72(9):3013-3027. doi: 10.1007/s00262-023-03470-y. Epub 2023 Jun 9. Cancer Immunol Immunother. 2023. PMID: 37294342 Free PMC article. Clinical Trial.
Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptor-positive breast cancer.
Egelston CA, Guo W, Tan J, Avalos C, Simons DL, Lim MH, Huang YJ, Nelson MS, Chowdhury A, Schmolze DB, Yim JH, Kruper L, Melstrom L, Margolin K, Mortimer JE, Yuan Y, Waisman JR, Lee PP. Egelston CA, et al. Among authors: schmolze db. JCI Insight. 2022 Feb 8;7(3):e153963. doi: 10.1172/jci.insight.153963. JCI Insight. 2022. PMID: 35132960 Free PMC article.
57 results